The present study investigated the prognostic biomarkers FGFR2, VEGF, TRAIL-R1, and TRAIL-R2 alongside clinicopathological data to improve outcome prediction in patients with resected HCC. The gene discussed is FGFR2; the disease is hepatocellular carcinoma.